Radiopharmaceuticals is experiencing rapid growth nationally and is poised for greater investment and breakthroughs in patient care.
The Nuclear Medicine Symposium positions Greater Philadelphia as a hub for innovation at the intersection of science, clinical practice, and industry. Whether you are advancing research, delivering care, commercializing new technologies, or investing in what’s next, this event brings together the voices to translating discovery into impact and accelerating progress.
Speakers and panelists for this event included
- Sumit Verma, TAG1 Inc. and Orchestra Life Sciences
- John Swartley, MBA, PhD, Penn Center for Innovation
- Audrey Greenberg, Mayo Clinic
- James M. Metz, MD, University of Pennsylvania Perelman School of Medicine
- Reid Tanaka, TerraPower
- Carl v. Gall, MD, Siemens Healthineers
- Christopher Molineaux, LSPA
- Jon A. Epstein, MD, University of Pennsylvania Perelman School of Medicine
- Steve Hahn, MD, Nucleus RadioPharma
- Jeff Marrazzo, Dispatch Bio
- Mark Mintun, MD, Avid Radiopharmaceuticals/Eli Lilly and Company
- Claire Marrazzo Greenwood, Chamber & CEO Council for Growth
- John Grady, Wexford Science & Technology
Nuclear Medicine at uCity Square: Avid Pharmaceuticals
Avid Radiopharmaceuticals develops FDA‑approved PET imaging diagnostics that enable early disease detection, monitor treatment response, and support drug development through innovative diagnostic science.